Updates are available Correction dated 2026-03-03
Click to view Correction: https://doi.org/10.1038/s41477-026-02255-2
-
Authors
Toth, Ryan
Choi, Sera
Le Naour--Vernet, Marie https://orcid.org/0000-0003-4923-8039
Schwanke, Florian
Johnson, Jared L. https://orcid.org/0000-0003-1802-6527
Tee, Estee E. https://orcid.org/0000-0003-2613-5977
Yaron-Barir, Tomer M. https://orcid.org/0000-0001-6574-7314
Khochaba, Eleanor
Derbyshire, Paul https://orcid.org/0000-0002-5095-9397
Colo, Anka
Köster, Philipp
Huntsman, Emily M.
Herold, Laura
Lee, Yoonyoung https://orcid.org/0000-0002-5080-7633
Fernández-Fernández, Álvaro D. https://orcid.org/0000-0003-4770-9757
Ahn, Hee-Kyung https://orcid.org/0000-0002-8884-0156
Dindas, Julian https://orcid.org/0000-0003-3078-4865
Bjornson, Marta https://orcid.org/0000-0002-8275-4521
Rhodes, Jack https://orcid.org/0000-0002-3953-1648
Song, Beibei
Wang, Weibing
Smokvarska, Marija
Bayer, Emmanuelle M. https://orcid.org/0000-0001-8642-5293
Zhou, Jian-Min https://orcid.org/0000-0002-9943-2975
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Jones, Jonathan D. G. https://orcid.org/0000-0002-4953-261X
Bender, Kyle W. https://orcid.org/0000-0002-1805-8097
Menke, Frank L. H. https://orcid.org/0000-0003-2490-4824
Faulkner, Christine https://orcid.org/0000-0003-3905-8077
Zipfel, Cyril https://orcid.org/0000-0003-4935-8583
DeFalco, Thomas A. https://orcid.org/0000-0003-2897-1485
- License Information
-
More Information
Article History
Received: 1 November 2025
Accepted: 18 December 2025
First Online: 9 February 2026
Change Date: 3 March 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41477-026-02255-2
Competing interests
: L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals; is a founder of and receives research support from Petra Pharmaceuticals; is listed as an inventor on a patent (WO2019232403A1, Weill Cornell Medicine) for combination therapy for phosphoinositide 3-kinase (PI3K)-associated disease or disorder and the identification of therapeutic interventions to improve response to PI3K inhibitors for cancer treatment; is a co-founder of and shareholder in Faeth Therapeutics; has equity in and consults for Cell Signaling Technologies, Volastra, Larkspur and 1 Base Pharmaceuticals; and consults for Loxo-Lilly. T.M.Y. is a co-founder of DeStroke. J.L.J. has received consulting fees from Scorpion Therapeutics and Volastra Therapeutics.
